3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU

Acute right ventricular (RV) failure is a catastrophic hemodynamic syndrome characterized by the inability of the right ventricle to generate adequate forward stroke volume to maintain left ventricular filling, leading to systemic venous congestion, tissue hypoperfusion, and cardiogenic shock. In the intensive care unit, acute RV failure may occur as de novo decompensation (e.g., massive pulmonary embolism, acute respiratory distress syndrome) or as an acute-on-chronic crisis in patients with underlying pulmonary arterial hypertension (PAH).

---

Classification & Hemodynamics of Pulmonary Hypertension

Pulmonary hypertension (PH) is defined hemodynamically by a resting mean pulmonary artery pressure (mPAP) $>20\text{ mmHg}$ measured via right heart catheterization.

Hemodynamic Phenotypes

• Pre-Capillary PH: Defined by $\text{mPAP} > 20\text{ mmHg}$, Pulmonary Arterial Wedge Pressure ($\text{PAWP} \le 15\text{ mmHg}$), and Pulmonary Vascular Resistance ($\text{PVR} > 2\text{ Wood Units}$; 2022 ESC/ERS). Typical of WHO Groups 1, 3, 4, and 5.
• Post-Capillary PH: Defined by $\text{mPAP} > 20\text{ mmHg}$ and $\text{PAWP} > 15\text{ mmHg}$. Driven by elevated left-sided filling pressures (WHO Group 2). Subdivided into:
  • Isolated Post-Capillary PH (IpcPH): $\text{PVR} \le 2\text{ Wood Units}$.
  • Combined Post- and Pre-Capillary PH (CpcPH): $\text{PVR} > 2\text{ Wood Units}$, indicating reactive vascular remodeling.

The Five WHO Diagnostic Groups

WHO Pulmonary Hypertension Diagnostic Classification:
├── Group 1: Pulmonary Arterial Hypertension (PAH)
│   └── Idiopathic, heritable, drug/toxin-induced, connective tissue disease (scleroderma), HIV, portal hypertension
├── Group 2: PH Secondary to Left Heart Disease (Most Common)
│   └── Heart failure with preserved ejection fraction (HFpEF), HFrEF, mitral/aortic valvular disease
├── Group 3: PH Secondary to Lung Diseases and/or Hypoxia
│   └── COPD, interstitial lung disease (ILD), obstructive sleep apnea, chronic high-altitude exposure
├── Group 4: Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
│   └── Recurrent/unresolved pulmonary thromboemboli, amenable to pulmonary thromboendarterectomy (PTE)
└── Group 5: PH with Unclear or Multifactorial Mechanisms
    └── Hematologic disorders (myeloproliferative diseases), sarcoidosis, histiocytosis X, chronic renal failure

---

The Biomechanics of the RV & the "Death Spiral"

Unique RV Anatomy and Physiology

The right ventricle is a thin-walled, compliant, crescent-shaped pump wrapped around the muscular, conical left ventricle. Under normal physiological conditions:

• The RV operates against a low-pressure, highly distensible pulmonary vascular bed with a resistance approximately one-tenth that of the systemic circulation.
• Unlike the left ventricle (which is perfused by coronary flow almost exclusively during diastole), the thin-walled RV is perfused by the right coronary artery (RCA) during both systole and diastole because normal RV peak systolic pressure ($20–25\text{ mmHg}$) is far below systemic aortic systolic pressure ($100–120\text{ mmHg}$).
• The RV adapts poorly to acute spikes in afterload. An acute elevation in PVR rapidly overpowers the contractile reserve of the non-hypertrophied RV.

The Pathophysiologic Cascade of the RV Death Spiral

                         Acute Increase in RV Afterload (PVR)
                                       │
                                       ▼
                    Acute RV Dilation & Wall Tension Spikes
                        (Laplace's Law: σ = P·r / 2h)
                                       │
                                       ▼
                    Severe Functional Tricuspid Regurgitation
                                       │
                                       ▼
                           Ventricular Interdependence
               (Septum shifts leftward into LV → "D-shaped" LV)
                                       │
                                       ▼
                     Impaired LV Diastolic Filling & Preload
                                       │
                                       ▼
                    Marked Fall in Cardiac Output & SBP (MAP)
                                       │
                                       ▼
                 Severe Drop in RV Coronary Perfusion Pressure
                           (CPPRV = MAP - RVSP ≤ 0)
                                       │
                                       ▼
                      RV Subendocardial Myocardial Ischemia
                                       │
                                       ▼
                Worsening RV Contractile Failure → PEA Arrest

1. Afterload Spike: Acute increases in PVR (from PE, hypoxia, hypercapnia, acidosis, or high intrathoracic ventilator pressure) cause acute RV afterload mismatch.
2. Chamber Dilation & Tricuspid Regurgitation: The RV dilates to recruit preload via the Frank-Starling mechanism. However, as it dilates, the tricuspid valve annulus widens, producing severe, functional tricuspid regurgitation. Blood regurgitates into the right atrium, driving central venous pressure (CVP) upwards of $18–25\text{ mmHg}$ and causing end-organ venous congestion.
3. Ventricular Interdependence: Because both ventricles share common circumferential myocardial fibers, the interventricular septum, and a non-distensible pericardium, RV dilatation shifts the interventricular septum toward the left ventricular cavity. On short-axis echocardiography, the LV assumes a characteristic "D-shaped" morphology in diastole, restricting LV volume, lowering LV compliance, and drastically reducing LV end-diastolic volume (preload).
4. Cardiogenic Shock & Ischemia: Compromised LV filling causes systemic cardiac output and mean arterial pressure (MAP) to plummet. Concurrently, RV systolic pressure (RVSP) rises to equal or exceed systemic pressure. The perfusion pressure of the right ventricle is governed by:

$\text{CPP}_{\text{RV}} = \text{MAP} - \text{RVSP}$

When RVSP approaches MAP, RCA flow during systole ceases entirely; perfusion is restricted to a brief diastolic window. This produces profound RV subendocardial ischemia, culminating in fatal electromechanical dissociation.

---

Principles of RV-Directed Resuscitation in the ICU

Management of the failing right ventricle requires a strict, physiologically driven resuscitation protocol anchored on four therapeutic goals:

Four Pillars of RV Resuscitation:
├── 1. Preload Optimization: Strict volume limitation; judicious diuresis for congestion
├── 2. Systemic Perfusion: Maintain MAP > mPAP (target MAP 65–75 mmHg) with norepinephrine/vasopressin
├── 3. Inotropy: Augment RV contractility with low-dose dobutamine or milrinone (paired with vasopressor)
└── 4. Afterload Reduction: Inhaled epoprostenol or inhaled nitric oxide (avoid systemic vasodilators)

Pillar 1: Preload Optimization

• Fluid Challenge: Only indicated if the patient has unambiguous evidence of hypovolemia (e.g., CVP $<8\text{ mmHg}$, flat non-distended IVC). If attempted, volume should be administered in small, monitored aliquots of $250\text{ mL}$ crystalloid.
• Volume Overload Decompression: When CVP is elevated ($>12–15\text{ mmHg}$) and physical exam confirms systemic congestion (hepatomegaly, ascites, peripheral edema), careful diuresis with intravenous loop diuretics (furosemide) or continuous venovenous ultrafiltration (CRRT) is paradoxically life-saving. Decompressing the RV relieves interventricular septal flattening, restores LV diastolic filling, and augments systemic cardiac output.

Pillar 2: Restoring Systemic Perfusion Pressure

To restore right coronary artery perfusion, mean arterial pressure must be vigorously defended to ensure $\text{MAP} > \text{mPAP}$ (typically targeting $\text{MAP} \ge 65–75\text{ mmHg}$):

• Norepinephrine: The first-line vasopressor in acute RV failure. By stimulating vascular $\alpha_1$ receptors, it elevates systemic vascular resistance (SVR) and aortic diastolic pressure, immediately restoring RCA perfusion. Concomitant $\beta_1$ stimulation provides inotropic support to the RV without causing disproportionate increases in PVR.
• Vasopressin: An ideal second-line adjunct dosed at $0.01–0.03\text{ units/min}$. Vasopressin constricts systemic arterioles via vascular $V_1$ receptors while causing selective pulmonary vasodilation at low doses through endothelial nitric oxide release, effectively raising MAP without elevating PVR.
• Agents to Avoid: Pure $\alpha_1$ agonists like phenylephrine are generally avoided as sole agents because they can raise PVR and provide no inotropy; vasopressin or norepinephrine is preferred to support systemic pressure.

Pillar 3: Augmenting RV Inotropy

• Dobutamine: Initiated at low doses ($2–5\ \mu\text{g/kg/min}$). Stimulates myocardial $\beta_1$ receptors, augmenting RV contractility and reducing PVR via mild $\beta_2$ vasodilation. Doses above $10\ \mu\text{g/kg/min}$ should be avoided due to tachycardia and peripheral vasodilation.
• Milrinone: A phosphodiesterase-3 (PDE-3) inhibitor. It prevents cAMP degradation, providing powerful combined inotropy and pulmonary afterload reduction ("inodilator"). However, milrinone has a long elimination half-life ($2–4\text{ hours}$), is eliminated renally, and causes substantial systemic arterial vasodilation. Milrinone must always be paired with norepinephrine to prevent systemic hypotension. Inhaled milrinone can be considered to deliver selective pulmonary vasodilation without systemic hypotension.

Pillar 4: Selective Pulmonary Vasodilation

Systemic vasodilators (calcium channel blockers, intravenous nitroglycerin, intravenous hydralazine, and newly started oral sildenafil) should be avoided in hypotensive acute RV failure because they lower systemic pressure, and therefore RV coronary perfusion, before producing meaningful pulmonary vasodilation. Therapy must rely on inhaled agents that selectively target ventilated pulmonary segments:

• Inhaled Epoprostenol (Prostacyclin / PGI2): Delivered via continuous vibrating-mesh nebulizer at $10–50\text{ ng/kg/min}$. It activates smooth muscle adenylate cyclase, increasing intracellular cAMP and dilating intra-alveolar pulmonary vessels. It significantly improves ventilation-perfusion matching and reduces RV afterload.
• Inhaled Nitric Oxide (iNO): Delivered at $10–40\text{ ppm}$. It activates soluble guanylyl cyclase to increase cGMP. It has an ultra-short half-life (several seconds) because it is immediately inactivated upon entering the bloodstream by binding to hemoglobin, preventing any systemic vasodilation.

---

Mechanical Ventilation in the Failing RV

Endotracheal intubation is an exceptionally high-risk event in severe RV failure. The combination of sedative-induced loss of sympathetic tone and positive-pressure mechanical ventilation can trigger instantaneous circulatory arrest.

The "Killers of the Right Ventricle"

---

Mechanical Circulatory Support for Refractory RV Failure

When medical management fails to arrest the RV death spiral, advanced mechanical circulatory support must be deployed rapidly:

1. Percutaneous Right Ventricular Assist Device (RVAD): Systems such as the Impella RP or ProtekDuo with TandemHeart drain venous blood directly from the right atrium or inferior vena cava and pump it directly into the main pulmonary artery, actively bypassing the failing right ventricle and restoring left-sided filling.
2. Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO): Provides complete circulatory and respiratory support. Blood is withdrawn from the right atrium via a femoral venous cannula, passed through an extracorporeal membrane oxygenator, and returned under high pressure into the femoral artery. VA-ECMO fully decompresses the right heart, restores systemic organ perfusion, and provides an immediate bridge to recovery, lung transplantation, or pulmonary thromboendarterectomy.